A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 108-117

  Hsu, Chia Yang ^a,b   Huang, Yi Hsiang ^a,b   Hsia, Cheng Yuan ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Loong, Che Chuan ^a,b   Chiou, Yi You ^a,b   Chiang, Jen Huey ^a,b   Lee, Pui Ching ^b   Huo, Teh Ia ^a,b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Fetoprotein; Child Turcotte Pugh; Cirrhosis; Hepatocellular carcinoma; Model for end stage liver disease (MELD); Sodium; Total tumor volume

Indexed keywords

ACETIC ACID; ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; SODIUM; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BARCELONA CLINIC LIVER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER OF THE LIVER ITALIAN PROGRAM; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; JAPAN INTEGRATED SCORING SYSTEM; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SCORING SYSTEM; TAIPEI INTEGRATED SCORING SYSTEM; TOKYO SYSTEM; TUMOR VOLUME; AGED; BIOLOGICAL MODEL; BLOOD; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; TAIWAN;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SODIUM; TAIWAN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; KAPLAN-MEIER ESTIMATE;

EID: 77953120359     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.038     Document Type: Article

References (43)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. Cillo U., Vitale A., Grigoletto F., Farinati F., Brolese A., Zanus G., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44 (2006) 723-731
4. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10 (2 Suppl. 1):S115-20.
5. Ueno S., Tanabe G., Sako K., Hiwaki T., Hokotate H., Fukukura Y., et al. Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 34 (2001) 529-534
6. Kudo M., Chung H., Haji S., Osaki Y., Oka H., Seki T., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
7. Tateishi R., Yoshida H., Shiina S., Imamura H., Hasegawa K., Teratani T., et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54 (2005) 419-425
8. Toso C., Asthana S., Bigam D.L., Shapiro A.M., and Kneteman N.M. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 49 (2009) 832-838
9. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
10. Toso C., Trotter J., Wei A., Bigam D.L., Shah S., Lancaster J., et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transplant 14 (2008) 1107-1115
11. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
12. Huo T.I., Wu J.C., Lin H.C., Lee F.Y., Hou M.C., Lee P.C., et al. Evaluation of the increase in model for end-stage liver disease (deltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 42 (2005) 826-832
13. Biggins S.W., Kim W.R., Terrault N.A., Saab S., Balan V., Schiano T., et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130 (2006) 1652-1660
14. Kim W.R., Biggins S.W., Kremers W.K., Wiesner R.H., Kamath P.S., Benson J.T., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359 (2008) 1018-1026
15. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
16. Grant B.F., Dufour M.C., and Harford T.C. Epidemiology of alcoholic liver disease. Semin Liver Dis 8 (1988) 12-25
17. Huo T.I., Lin H.C., Lee F.Y., Hou M.C., Lee P.C., Wu J.C., et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int 26 (2006) 55-61
18. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., and Blei A.T. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35 (2002) 716-721
19. Kikuchi L.O., Paranagua-Vezozzo D.C., Chagas A.L., Mello E.S., Alves V.A., Farias A.Q., et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastroenterol 43 (2009) 191-195
20. Huo T.I., Huang Y.H., Lin H.C., Wu J.C., Chiang J.H., Lee P.C., et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 101 (2006) 975-982
21. Hosmer D.W., Hosmer T., Le Cessie S., and Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16 (1997) 965-980
22. Feinstein A.R. Clinical biostatistics. XVI. The process of prognostic stratification. Clin Pharmacol Ther 13 (1972) 609-624
23. Forster M.R. Key concepts in model selection: performance and generalizability. J Math Psychol 44 (2000) 205-231
24. Yeh C.N., Chen M.F., Lee W.C., and Jeng L.B. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol 81 (2002) 195-202
25. Zavaglia C., De Carlis L., Alberti A.B., Minola E., Belli L.S., Slim A.O., et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100 (2005) 2708-2716
26. Huo T.I., Lin H.C., Huang Y.H., Wu J.C., Chiang J.H., Lee P.C., et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 107 (2006) 141-148
27. Angermayr B., Cejna M., Karnel F., Gschwantler M., Koenig F., Pidlich J., et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52 (2003) 879-885
28. Llado L., Figueras J., Memba R., Xiol X., Baliellas C., Vazquez S., et al. Is MELD really the definitive score for liver allocation?. Liver Transplant 8 (2002) 795-798
29. Cholongitas E., Marelli L., Shusang V., Senzolo M., Rolles K., Patch D., et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transplant 12 (2006) 1049-1061
30. D'Amico G., Morabito A., Pagliaro L., and Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31 (1986) 468-475
31. Fernandez-Rodriguez C.M., Prieto J., Zozaya J.M., Quiroga J., and Guitian R. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology 104 (1993) 1139-1145
32. Eckardt K.U. Renal failure in liver disease. Intensive Care Med 25 (1999) 5-14
33. Papadakis M.A., and Arieff A.I. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 82 (1987) 945-952
34. Somsouk M., Guy J., Biggins S.W., Vittinghoff E., Kohn M.A., and Inadomi J.M. Ascites improves upon serum sodium and MELD for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther 30 (2009) 741-749
35. Porcel A., Diaz F., Rendon P., Macias M., Martin-Herrera L., and Giron-Gonzalez J.A. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Int Med 162 (2002) 323-328
36. Arroyo V., and Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38 (2003) S69-S89
37. Yen Y.H., Changchien C.S., Wang J.H., Kee K.M., Hung C.H., Hu T.H., et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis 41 (2009) 431-441
38. Tangkijvanich P., Anukulkarnkusol N., Suwangool P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31 (2000) 302-308
39. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009) 1012-1024
40. Wu J.C., Huang Y.H., Chau G.Y., Su C.W., Lai C.R., Lee P.C., et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51 (2009) 890-897
41. Akashi Y., Koreeda C., Enomoto S., Uchiyama S., Mizuno T., Shiozaki Y., et al. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology 14 (1991) 262-268
42. N'kontchou G., Mahamoudi A., Aout M., Ganne-Carrié N., Grando V., Coderc E., et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50 (2009) 1475-1483
43. Vora S.R., Zheng H., Stadler Z.K., Fuchs C.S., and Zhu A.X. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 14 (2009) 717-725